Table 2.
Baseline patient characteristics and variations between centers
| Total | Development cohort | Validation cohort | p value | ||
|---|---|---|---|---|---|
| Total, n (%) |
n = 509 (100%) |
n = 412 (81%) |
n = 97 (19%) | ||
| Sex, n (%) | Female | 177 (35%) | 139 (34%) | 38 (39%) | 0.37* |
| Male | 332 (65%) | 273 (66%) | 59 (61%) | ||
| Age, median (range) | 65 (25-87) | 66 (25-87) | 65 (33-81) | 0.37** | |
| cT, n (%) | 1-2 | 35 (7%) | 30 (7%) | 5 (5%) | 0.57** |
| 3 | 441 (81%) | 334 (81%) | 80 (83%) | ||
| 4 | 60 (12%) | 48 (12%) | 12 (12%) | ||
| cN, n (%) | 0 | 68 (13%) | 52 (13%) | 16 (17%) | 0.98** |
| 1 | 122 (24%) | 103 (25%) | 19 (20%) | ||
| 2 | 319 (63%) | 257 (62%) | 62 (64%) | ||
| Complete response, n (%) | CR | 141(28%) | 111 (27%) | 30 (31%) | 0.51* |
| Not-CR | 368 (72%) | 301 (73%) | 67 (69%) | ||
| Good response, n (%) | Good | 225 (44%) | 184 (45%) | 41 (42%) | 0.75* |
| Poor | 284 (56%) | 228 (55%) | 56 (58%) | ||
*Calculated using chi-squared test
** Calculated using the Kruskal-Wallis test